» Articles » PMID: 36808002

Predictive Value of F-FDG PET/CT-based Radiomics Model for Neoadjuvant Chemotherapy Efficacy in Breast Cancer: a Multi-scanner/center Study with External Validation

Overview
Date 2023 Feb 22
PMID 36808002
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To develop and validate the predictive value of an F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) model for breast cancer neoadjuvant chemotherapy (NAC) efficacy based on the tumor-to-liver ratio (TLR) radiomic features and multiple data pre-processing methods.

Methods: One hundred and ninety-three breast cancer patients from multiple centers were retrospectively included in this study. According to the endpoint of NAC, we divided the patients into pathological complete remission (pCR) and non-pCR groups. All patients underwent F-FDG PET/CT imaging before NAC treatment, and CT and PET images volume of interest (VOI) segmentation by manual segmentation and semi-automated absolute threshold segmentation, respectively. Then, feature extraction of VOI was performed with the pyradiomics package. A total of 630 models were created based on the source of radiomic features, the elimination of the batch effect approach, and the discretization method. The differences in data pre-processing approaches were compared and analyzed to identify the best-performing model, which was further tested by the permutation test.

Results: A variety of data pre-processing methods contributed in varying degrees to the improvement of model effects. Among them, TLR radiomic features and Combat and Limma methods that eliminate batch effects could enhance the model prediction overall, and data discretization could be used as a potential method that can further optimize the model. A total of seven excellent models were selected and then based on the AUC of each model in the four test sets and their standard deviations, we selected the optimal model. The optimal model predicted AUC between 0.7 and 0.77 for the four test groups, with p-values less than 0.05 for the permutation test.

Conclusion: It is necessary to enhance the predictive effect of the model by eliminating confounding factors through data pre-processing. The model developed in this way is effective in predicting the efficacy of NAC for breast cancer.

Citing Articles

F-FDG PET/CT-based intratumoral and peritumoral radiomics combining ensemble learning for prognosis prediction in hepatocellular carcinoma: a multi-center study.

Sui C, Chen K, Ding E, Tan R, Li Y, Shen J BMC Cancer. 2025; 25(1):300.

PMID: 39972270 PMC: 11841186. DOI: 10.1186/s12885-025-13649-4.


Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on F-FDG PET/CT.

Hou X, Chen K, Wan X, Luo H, Li X, Xu W J Cancer Res Clin Oncol. 2024; 150(11):484.

PMID: 39488636 PMC: 11531439. DOI: 10.1007/s00432-024-05987-w.


Radiomics based on F-FDG PET/CT for prediction of pathological complete response to neoadjuvant therapy in non-small cell lung cancer.

Liu J, Sui C, Bian H, Li Y, Wang Z, Fu J Front Oncol. 2024; 14:1425837.

PMID: 39132503 PMC: 11310012. DOI: 10.3389/fonc.2024.1425837.


MRI-based intratumoral and peritumoral radiomics for preoperative prediction of glioma grade: a multicenter study.

Tan R, Sui C, Wang C, Zhu T Front Oncol. 2024; 14:1401977.

PMID: 38803534 PMC: 11128562. DOI: 10.3389/fonc.2024.1401977.


Pretreatment multiparametric MRI radiomics-integrated clinical hematological biomarkers can predict early rapid metastasis in patients with nasopharyngeal carcinoma.

Cao X, Wang X, Song J, Su Y, Wang L, Yin Y BMC Cancer. 2024; 24(1):435.

PMID: 38589858 PMC: 11003025. DOI: 10.1186/s12885-024-12209-6.


References
1.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

2.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

3.
Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R . PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019; 46(7):1468-1477. DOI: 10.1007/s00259-019-04313-8. View

4.
Mao N, Shi Y, Lian C, Wang Z, Zhang K, Xie H . Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on contrast-enhanced spectral mammography. Eur Radiol. 2022; 32(5):3207-3219. DOI: 10.1007/s00330-021-08414-7. View

5.
Jiang M, Li C, Luo X, Chuan Z, Lv W, Li X . Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer. 2021; 147:95-105. DOI: 10.1016/j.ejca.2021.01.028. View